对比TACE联合^(125)I粒子与联合仑伐替尼治疗肝细胞癌伴门静脉癌栓的有效性及安全性  

Comparison on efficacy and safety of TACE combined with^(125)I seeds implantation or lenvatinib for treating hepatocellular carcinoma complicated with portal vein tumor thrombosis

作　　者：孙维玮 李威[1] 满文玲 董畅 杨坡[1] SUN Weiwei;LI Wei;MAN Wenling;DONG Chang;YANG Po(Department of Interventional Vascular Surgery,the Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第四医院介入血管外科,黑龙江哈尔滨150001

出　　处：《中国介入影像与治疗学》2023年第12期713-717,共5页Chinese Journal of Interventional Imaging and Therapy

摘　　要：目的对比TACE联合^(125)I粒子植入或仑伐替尼治疗肝细胞癌(HCC)伴门静脉癌栓(PVTT)的有效性及安全性。方法回顾性分析52例HCC伴Ⅱ/Ⅲ型PVTT患者,分为TACE联合^(125)I粒子组(A组,n=27)及TACE联合仑伐替尼组(B组,n=25);比较2组客观缓解率(ORR)、总生存期(OS)及不良反应率。结果A组ORR、中位OS、Ⅱ型PVTT中位OS及Ⅲ型PVTT中位OS分别为70.37%(19/27)、13.6个月、14.1个月及13.2个月;B组分别为32.00%(8/25)、11.3个月、12.3个月及10.4个月;A组上述指标均优于B组(P均<0.05)。A组不良反应发生率为48.15%(13/27),均未见严重并发症;B组不良反应发生率为88.00%(22/25),5例(5/25,20.00%)出现严重药物毒性反应。结论TACE联合^(125)I粒子治疗HCC伴PVTT的有效性及安全性均优于TACE联合仑伐替尼。Objective To comparatively observe the efficacy and safety of TACE combined with^(125)I seeds implantation or lenvatinib for treating hepatocellular carcinoma(HCC)complicated with portal vein tumor thrombosis(PVTT).Methods Totally 52 HCC patients complicated with typeⅡor typeⅢPVTT were enrolled and divided into TACE combined with^(125)I seeds group(group A,n=27)and TACE combined with lenvatinib group(group B,n=25).Objective response rate(ORR),overall survival(OS)and incidence rate of adverse reaction were compared between groups.Results ORR,the median OS,median OS of typeⅡPVTT and median OS of typeⅢPVTT was 70.37%(19/27),13.6 months,14.1 months and 13.2 months in group A,and 32.00%(8/25),11.3 months,12.3 months and 10.4 months in group B,respectively.The above indexes in group A were all better than those in group B(all P<0.05).In group A,the incidence rate of adverse reaction was 48.15%(13/27),and no serious complication occurred.In group B,the incidence rate of adverse reaction was 88.00%(22/25),and severe drug toxicity was noticed in 5 cases(5/25,20.00%).Conclusion The efficacy and safety of TACE combined with^(125)I seeds were both better than those of TACE combined with lenvatinib for treating HCC complicated with PVTT.

关 键 词：癌 肝细胞 门静脉癌栓 化学栓塞 治疗性 碘同位素 

分 类 号：R735.7[医药卫生—肿瘤] R815[医药卫生—临床医学]